We need to do a phase 1 again to determine safety and dose. You need to make sure the dose you are administering is safe on the individuals and in correct concentration. You can’t dose a TBI patient without first determining these parameters before hand. We cannot just guess doesn’t work that way
AGN will need to do phase 1 again for TBI. But to spend 4 million dollars will take away from the development for phase 2 studies on Stroke. We will be 7-8 years behind NYR if all funding for AGN is focused on stroke 15 percent of stroke patients. But again there is nothing out there for brain injury it’s why AGN CEO is confident that after phase 2 it will be a billion dollar plus company
AGN will succeed in proving that inhibiting calcium uptake in brain cells during injury works that’s for sure. NYR has already backed up AGN claim in its pre clinical, in vitro and invivo studies
AGN Price at posting:
81.0¢ Sentiment: Buy Disclosure: Held
(20min delay)